Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076082 · ClinicalTrials.gov registry record · Phase 4
Vascular Trial Associated Registry Pilot
A Phase 4 study of Peripheral Arterial Disease, sponsored by Corewell Health West.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
- 2
- Study locations
NCT07076082 is a Phase 4 study of Peripheral Arterial Disease that is actively recruiting participants, run by Corewell Health West. The registered enrollment target is 350 participants, below the 4,202-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07076082, a Phase 4 study of Peripheral Arterial Disease, is actively recruiting participants, sponsored by Corewell Health West.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.
Conditions Studied
Interventions
- DRUG Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Study Locations (2)
Michigan
- Henry Ford Hospital - Detroit
- Corewell Health - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07076082
The ClinicalTrials.gov registry entry for NCT07076082 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,202-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (92% lower). The listed sponsor is Corewell Health West, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Clopidogrel (Plavix) Pharmacogenetic Test Reagents is the first listed.
NCT07076082 reports 2 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07076082 about?
NCT07076082 is a clinical study titled "Vascular Trial Associated Registry Pilot". The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six m...
What is the current status of trial NCT07076082?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2025-10-15. Estimated completion is 2028-10-30.
What conditions does trial NCT07076082 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT07076082?
The interventions under investigation include: Clopidogrel (Plavix) Pharmacogenetic Test Reagents (DRUG).
Who is sponsoring clinical trial NCT07076082?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076082 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
ACTIVE NOT RECRUITING · Phase 4
-
The Jetstream G3™ Calcium Study
COMPLETED · Phase 4
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.